Compare HOLOW & BCTXZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOLOW | BCTXZ |
|---|---|---|
| Founded | N/A | N/A |
| Country | China | Canada |
| Employees | 74 | 4 |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | HOLOW | BCTXZ |
|---|---|---|
| Price | $0.07 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.3K | ★ 36.4K |
| Earning Date | 03-14-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,242,196.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 326.95 | N/A |
| 52 Week Low | $0.07 | $0.06 |
| 52 Week High | $0.23 | $1.20 |
| Indicator | HOLOW | BCTXZ |
|---|---|---|
| Relative Strength Index (RSI) | 30.39 | 41.60 |
| Support Level | N/A | $0.10 |
| Resistance Level | $0.11 | $0.16 |
| Average True Range (ATR) | 0.00 | 0.02 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 0.35 | 11.69 |
MicroCloud Hologram Inc provides holographic technology services. Its services include holographic light detection and ranging (LiDAR) solutions, holographic LiDAR point cloud algorithms architecture design, technical holographic imaging solutions, holographic LiDAR sensor chip design, and holographic vehicle intelligent vision technology to service customers that provide holographic driver assistance systems (ADAS). The company also provides holographic digital twin technology services for customers and has built a proprietary holographic digital twin technology resource library. MicroCloud's operating segments are: Holographic technology service, which generates maximum revenue, and Holographic solutions. Its revenues are mainly generated in the People's Republic of China (PRC).
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.